| abstract |
REFERS TO BENZIMIDAZOLE DERIVATIVE COMPOUNDS OF FORMULA (I), WHERE t IS 0, 1 OR 2; R IS H, RENT, AMONG OTHERS; R2 IS H, RENTAL, OPTIONALLY SUBSTITUTED, HALOALKYL, CYCLOALKYL, AMONG OTHERS; R3 IS OPTIONALLY SUBSTITUTED H OR RENT; m IS 0, 1 O 2; R4 IS HALOGEN, HALO RENT, AMONG OTHERS; p IS 0 O 1; Y IS C (O), -N (R10) -, -O-, -S-, -C (O) NR10-, AMONG OTHERS; X IS -RaN (R10) 2-, -AyRaN (R10) 2, -Het, -RaHet, -HetN (R10) 2, AMONG OTHERS. THE PREFERRED ARE: N- [2- (1H-IMIDAZOL-4-IL) ETHYL] -1-METHYL-2 - {[METHYL (5,6,7,8-TETRAHYDRO-8-QUINOLINYL) AMINO] METHYL} -1H -BENZIMIDAZOLE-7-CARBOXIAMIDE, N-METHYL-N - {[4- (1-PIPERAZINYL) -1H-BENZIMIDAZOL-2-IL] METHYL} -5,6,7,8-TETRAHYDRO-8-QUINOLINAMIDE, N- METHYL-N - ({4- [3- (1-PYRROLIDINYL) PROPYL] -1H-BENZYMIDAZOL-2-IL} METHYL) -5,6,7,8-TETRAHYDRO-8-QUINOLINAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCESS AND A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE PROTECTIVE ON TARGET CELLS AGAINST HIV INFECTION, BECAUSE THEY ARE SPECIFICALLY BINDING TO THE CHEMOKINE RECEPTOR AND AFFECTING THE BINDING OF THE NATURAL LIGAND OR CHEMOQUIN AND AFFECTING THE BINDING OF THE NATURAL LIGAND OR CHEMOQUTOR4, LIKE A CEPT-CRYST RECEPTOR AND / OR CCR5, IN A TARGET CELL |